skingenix
Application on Burn Wounds
The following instructions illustrated the standard practice and outcomes experienced in MEBO treatment.  For the investigational use of MEBO in the US, please refer to specific clinical study protocol where the clinical procedures are specifically defined and standardized.
 
 
       
     MEBO Application in Deep 2nd Degree Burns
 
 

 
 
1. After simple debridement, immediately apply MEBO to protect the wounds.
 

 
 
2. On 5th ¨C 7th day postburn, gently remove the blister skin. Necrotic tissues start to be liquefied and discharged. A thin soft fiber membrane is formed on the wound under the actions of MEBO. Continue applying MEBO and protect the thin soft membrane.
 

 
 
3. On the 20th day postburn, wound healed with regenerated skin.
 
 

 
 
4. Continue applying MEBO as a protection for 10-15 days. Hypo-pigmentation is noted.
 
 


 

MEBO Application in 3rd Degree Burns
 
 

 
 
1. The patient has 85% TBSA 3rd degree burns. Wound pathological exam shows full thickness necrosis (fig a, b, c).
 

 
 
2. ¡®Wound ploughing¡¯ is performed for relieving pressure on underlying tissues by using specially designed ¡®sawtooth cutter¡¯, followed by MEBO application.
 

 
 
3. Clean up the liquefied necrotic tissues before redressing MEBO. The pathological section shows new skin structure has been rebuilding on day 20. (fig e, f) 

 

 
 
4. On day 25, numerous ¡®skin islands¡¯ have emerged from regenerated skin tissues.
 
 

 
 
5. In the ¡®skin island¡¯, regenerative cells from subcutaneous tissue are robustly multiplying. Note capillaries, collagen, and epithelial cells.   
 

 
 
6. ¡®Skin islands¡¯ gradually extend and merger together.
 
.

 
 
7. On day 49, regenerated skin exhibits the normal skin structure in pathological slide.
 

 
 
8. On day 72, burn wounds have been healed completely with regenerated skin.
 
 
 
 
MEBO Application in 4th Degree Burns
 
 
 
 
1. Appearance of burned tibia of left leg.
 
 
 
 
 
 
2. Surgical excision of the necrotic tissues on bone surface.
 
 
 
 
 
 
3. Removal of the necrotic periosteum and outer cortex of tibia with scraper and bone chisel.
 
 
 
 
 
4. Multiple holes drilled on the exposed tibia surface in 1.0 cm apart; deep to viable marrow cavity; minor bleeding is expected.
 

 
 
 
5. Appearance of tibial surface after drilling.
 
 
 
 
 
 
6. Subsequent to the application of preserved gauze soaked with MEBO to cover the wound; small granulating buds grew up through the drilled holes within few days.
 
 
 
7. Continuous treatment with MEBO, the granulated tissues developed and spread to form a granulated wound. Skin grafting was then performed to close the wound.
 
Copyright © 2009-2010 SKINGENIXWEB.COM. All Rights Reserved
The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.